About TIVICAY®

(dolutegravir)

Why it might be
right for you

When taken in combination with other HIV-1 medicines, TIVICAY can help provide effective HIV-1 treatment in adults and children who weigh at least 66 pounds.

TIVICAY, taken in combination with other HIV-1 medications, may also help lower your viral load and increase your CD4 count. See results from two clinical studies below.

STUDY 1

In one clinical study, called SINGLE, with 833 adult patients who had never taken HIV-1 treatment before, more patients got to less than 50 copies of HIV-1 RNA per milliliter of blood with TIVICAY 50 mg once daily and abacavir + lamivudine than with Atripla® at 144 weeks. The difference in results was driven primarily by the rates of discontinuation due to adverse events.

Individual results may vary.

Results at 144 weeks

 

Took TIVICAY + ABC/3TC*

Took Atripla

% of Patients
< 50 copies/mL

71%

63%

Average CD4
Cell Count
Increase from
Study Start

378
CD4 cells/mm3†

332
CD4 cells/mm3†

% of Patients Who
Stopped Treatment
Due to Side Effects

4%

14%

From 96 weeks to 144 weeks, patients knew which drug they were taking.

*ABC/3TC = abacavir/lamivudine.

The number of CD4 T-cells per cubic millimeter of blood.

"Treatment" means HIV‑1 medicines being given in the study.

Side effects through 144 weeks

 

Took TIVICAY

Took Atripla

Most common
medium to
severe side
effects

3% of patients
had trouble sleeping.

2% of patients
experienced
headaches.

2% of patients
experienced tiredness.

3% of patients
had trouble sleeping.

2% of patients
experienced
headaches.

2% of patients
experienced tiredness.

Most common
mild side effect

7% of patients
had trouble sleeping.

4% of patients
had trouble sleeping.

Of course, your experience may be different. Make sure to tell your healthcare provider of any side effects you experience.

Study 2

Ready to find out if TIVICAY might be an HIV-1 treatment option for you? Check out the Talk About Treatment page for questions to help you start a conversation with your healthcare provider about HIV-1 treatment.

STUDY 2

In another clinical study, called SPRING-2, with 822* adult patients who had never taken HIV-1 treatment before, TIVICAY worked as well as raltegravir in getting patients to less than 50 copies of HIV-1 RNA in a milliliter of blood when taken with either abacavir/lamivudine or emtricitabine/tenofovir.

Individual results may vary.

Results at 96 weeks

 

Took TIVICAY

Took Raltegravir

% of Patients
< 50 copies/mL

82%

78%

Median CD4
Cell Count
Increase from
Study Start

276
CD4 cells/mm3‡

264
CD4 cells/mm3‡

% of Patients Who
Stopped Treatment§
Due to Side Effects

2%

2%

*808 patients were included in the study results.

Taken with either abacavir/lamivudine or emtricitabine/tenofovir.

The number of CD4 T-cells per cubic millimeter of blood.

§"Treatment" means HIV‑1 medicines being given in the study.

Side effects through 96 weeks

 

Took TIVICAY

Took Raltegravir

Most common
medium to
severe side
effects

1% of patients experienced nausea.

1% of patients experienced nausea.

Most common
mild side effect

1% of patients
had trouble sleeping.

<1% of patients
had trouble sleeping.

Of course, your experience may be different. Make sure to tell your healthcare provider of any side effects you experience.

Study 1

Ready to find out if TIVICAY might be an HIV-1 treatment option for you? Check out the Talk About Treatment page for questions to help you start a conversation with your healthcare provider about HIV-1 treatment.